AUPH שיעור רווח גולמי Aurinia Pharmaceuticals Inc

Planned gross margin helps assess the risks of Aurinia Pharmaceuticals (AUPH), whose revenues are heavily dependent on a single drug and regulatory restrictions. Competition with corporate behemoths is slowing brand expansion, however, 90.60 shows the current volume of this performance metric. High profitability and the exclusivity of renal pathology therapies provide the company with excellent scaling potential through an advanced distribution network.
פילוחי מדדים פיננסיים ומדדי שוק עבור Aurinia Corp (AUPH)

Gross margin is calculated as the ratio of the difference between revenue and cost of goods sold to total sales, measuring the efficiency of direct production. The current value of 90.60 reflects the ability of Aurinia Pharmaceuticals (AUPH) to maintain profitability amid dependence on a single drug and patent risks, making the gross profit margin history a key indicator of the business's resilience to competition.